Evidence map›Paper›PMID 26692525›Full record

ArticleTranslational oncology2015

Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.

Qiuting Wen, Laleh Jalilian, Janine M Lupo, Yan Li, Ritu Roy, Annette M Molinaro, Susan M Chang, Michael Prados, Nicholas Butowski, Jennifer Clarke and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Qiuting WenDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA United States; UCSF/UCB Joint Graduate Group in Bioengineering, University of California, San Francisco, San Francisco, CA United States.
Laleh JalilianDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA United States.
Janine M LupoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA United States.
Yan LiDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA United States.
Ritu RoyDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA United States; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA United States.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA United States; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA United States.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA United States.
Michael PradosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA United States.
Nicholas ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA United States.
Jennifer ClarkeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA United States.
Sarah J NelsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA United States; UCSF/UCB Joint Graduate Group in Bioengineering, University of California, San Francisco, San Francisco, CA United States; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA United States. Electronic address: sarah.nelson@ucsf.edu.
University of California, San Francisco · USNeurological Surgery · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Project 4: Multi-modality Metabolic Imaging for Monitoring Molecular Sub-types of GliomaP01CA118816 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Pavithra Viswanath · 2007 to 2026
$44.7M
MR Metabolic Markers for Evaluation of Patients with Recurrent GliomaR01CA127612 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, YAN · 2008 to 2017
$3.8M
NCI NIH HHS P01 CA118816NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA127612
6 · The paper itself

Abstract

purposeTo evaluate the time course and association with survival of anatomic lesion volumes and diffusion imaging parameters for patients with newly diagnosed glioblastoma who were treated with radiation and concurrently with either temozolomide and enzastaurin (TMZ+enza cohort) or temozolomide, erlotonib, and bevaciumab (TMZ+erl+bev cohort). MATERIALS AND

methodsRegions of interest corresponding to the contrast-enhancing and hyperintense lesions on T2-weighted images were generated. Diffusion-weighted images were processed to provide maps of apparent diffusion coefficient, fractional anisotropy, and longitudinal and radial eigenvalues. Histograms of diffusion values were generated and summary statistics calculated. Cox proportional hazards models were employed to assess the association of representative imaging parameters with survival with adjustments for age, Karnofsky performance status, and extent of resection.

resultsAlthough progression-free survival was significantly longer for the TMZ+erl+bev cohort (12.8 vs 7.3 months), there was no significant difference in overall survival between the two populations (17.0 vs 17.8 months). The median contrast-enhancing lesion volumes decreased from 6.3 to 1.9 cm(3) from baseline to the postradiotherapy scan for patients in the TMZ+enza cohort and from 2.8 to 0.9cm(3) for the TMZ+erl+bev cohort. Changes in the T2 lesion volumes were only significant for the latter cohort (26.5 to 11.9 cm(3)). The median apparent diffusion coefficient and related diffusion parameters were significantly increased for the TMZ+enza cohort (1054 to 1225 μm(2)/s). More of the anatomic parameters were associated with survival for the TMZ+enza cohort, whereas more diffusion parameters were associated with survival for the TMZ+erl+bev cohort.

conclusionThe early changes in anatomic and diffusion imaging parameters and their association with survival reflected differences in the mechanisms of action of the treatments that were being given. This suggests that integrating diffusion metrics and anatomic lesion volumes into the Response Assessment in Neuro-Oncology criteria would assist in interpreting treatment-induced changes and predicting outcome in patients with newly diagnosed glioblastoma who are receiving such combination treatments.

Identifiers

PMID26692525
PMCPMC4700297
OpenAlexW2193134845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.